Tigermed Reports 2024 Interim Results
Hangzhou Tigermed Consulting Co., (300347.SZ / 3347.HK), a leading clinical research solutions provider, reported its 2024 interim results. The company saw a clear quarter-on-quarter improvement in Q2 2024, with total revenue reaching 1,698 million RMB (2.3% increase), gross profit at 705 million RMB (12.2% increase), and net profit attributable to shareholders after deducting extraordinary gain or loss at 337 million RMB (11.3% increase).
For the first half of 2024, Tigermed achieved total revenue of 3,358 million RMB and gross profit of 1,333 million RMB. The company maintained its leading position in China's clinical service market with a 12.8% market share and expanded its global presence across 37 countries. Tigermed's clinical operations in North America, Asia-Pacific, and EMEA regions showed significant growth, with the company handling over 133 multi-region clinical trials.
Hangzhou Tigermed Consulting Co., (300347.SZ / 3347.HK), un fornitore leader di soluzioni per la ricerca clinica, ha riportato i suoi risultati intermedi per il 2024. L'azienda ha registrato un chiaro miglioramento trimestre su trimestre nel secondo trimestre del 2024, con un fatturato totale di 1.698 milioni di RMB (aumento del 2,3%), un utile lordo di 705 milioni di RMB (aumento del 12,2%) e un utile netto attribuibile agli azionisti, dedotte le plusvalenze o minusvalenze straordinarie, di 337 milioni di RMB (aumento dell'11,3%).
Per la prima metà del 2024, Tigermed ha raggiunto un fatturato totale di 3.358 milioni di RMB e un utile lordo di 1.333 milioni di RMB. L'azienda ha mantenuto la sua posizione di leadership nel mercato dei servizi clinici in Cina con una quota di mercato del 12,8% ed ha ampliato la propria presenza globale in 37 paesi. Le operazioni cliniche di Tigermed in Nord America, Asia-Pacifico e nella regione EMEA hanno mostrato una significativa crescita, con l'azienda che ha gestito oltre 133 studi clinici multi-regione.
Hangzhou Tigermed Consulting Co., (300347.SZ / 3347.HK), un proveedor líder de soluciones en investigación clínica, reportó sus resultados intermedios para 2024. La compañía vio una clara mejora trimestre a trimestre en el segundo trimestre de 2024, con ingresos totales alcanzando 1,698 millones de RMB (aumento del 2.3 %), ganancia bruta de 705 millones de RMB (aumento del 12.2 %) y una ganancia neta atribuible a los accionistas, después de deducir ganancias o pérdidas extraordinarias, de 337 millones de RMB (aumento del 11.3 %).
En la primera mitad de 2024, Tigermed logró ingresos totales de 3,358 millones de RMB y una ganancia bruta de 1,333 millones de RMB. La empresa mantuvo su posición de liderazgo en el mercado de servicios clínicos en China con una participación de mercado del 12.8 % y expandió su presencia global en 37 países. Las operaciones clínicas de Tigermed en América del Norte, Asia-Pacífico y la región EMEA mostraron un crecimiento significativo, gestionando más de 133 ensayos clínicos multi-regionales.
항저우 타이거메드 컨설팅(300347.SZ / 3347.HK)은 선도적인 임상 연구 솔루션 제공업체로서 2024년 중간 결과를 보고했습니다. 이 회사는 2024년 2분기 동안 분기 대비 뚜렷한 개선을 보였으며, 총 수익은 1,698백만 RMB(2.3% 증가), 총 이익은 705백만 RMB(12.2% 증가), 주주에게 귀속되는 순이익(비정상적 이익이나 손실을 공제한 후)은 337백만 RMB(11.3% 증가)에 달했습니다.
2024년 상반기 동안 타이거메드는 총 수익 3,358백만 RMB와 총 이익 1,333백만 RMB를 기록했습니다. 이 회사는 중국 임상 서비스 시장에서 선도적인 위치를 유지하며 시장 점유율 12.8%를 확보하고, 37개국에 걸쳐 글로벌 입지를 확장했습니다. 타이거메드의 북미, 아시아-태평양 및 EMEA 지역의 임상 운영은 상당한 성장을 보여주었으며, 이 회사는 133건 이상의 다지역 임상 시험을 관리하고 있습니다.
Hangzhou Tigermed Consulting Co., (300347.SZ / 3347.HK), un fournisseur leader de solutions de recherche clinique, a publié ses résultats intermédiaires pour 2024. L'entreprise a enregistré une amélioration nette d'un trimestre à l'autre au deuxième trimestre 2024, avec un chiffre d'affaires total atteignant 1.698 millions de RMB (augmentation de 2,3 %), un bénéfice brut de 705 millions de RMB (augmentation de 12,2 %) et un bénéfice net attribuable aux actionnaires, après déduction des gains ou pertes extraordinaires, de 337 millions de RMB (augmentation de 11,3 %).
Pour le premier semestre 2024, Tigermed a réalisé un chiffre d'affaires total de 3.358 millions de RMB et un bénéfice brut de 1.333 millions de RMB. L'entreprise a maintenu sa position de leader sur le marché des services cliniques en Chine avec une part de marché de 12,8 % et a élargi sa présence mondiale dans 37 pays. Les opérations cliniques de Tigermed en Amérique du Nord, en Asie-Pacifique et dans la région EMEA ont montré une croissance significative, l'entreprise ayant géré plus de 133 essais cliniques multi-régionaux.
Die Hangzhou Tigermed Consulting Co. (300347.SZ / 3347.HK), ein führender Anbieter von Lösungen für klinische Forschung, hat ihre Zwischenergebnisse für 2024 veröffentlicht. Das Unternehmen verzeichnete eine deutliche Verbesserung im Quartalsvergleich im 2. Quartal 2024, mit einem Gesamtumsatz von 1.698 Millionen RMB (Anstieg um 2,3 %), einem Bruttogewinn von 705 Millionen RMB (Anstieg um 12,2 %) und einem dem Aktionären zuzurechnenden Nettogewinn nach Abzug außergewöhnlicher Gewinne oder Verluste von 337 Millionen RMB (Anstieg um 11,3 %).
In der ersten Hälfte des Jahres 2024 erzielte Tigermed einen Gesamtumsatz von 3.358 Millionen RMB und einen Bruttogewinn von 1.333 Millionen RMB. Das Unternehmen behauptete seine führende Position im Markt für klinische Dienstleistungen in China mit einem Marktanteil von 12,8 % und erweiterte seine globale Präsenz in 37 Ländern. Die klinischen Operationen von Tigermed in Nordamerika, dem asiatisch-pazifischen Raum und der EMEA-Region zeigten ein signifikantes Wachstum, wobei das Unternehmen über 133 multiregionale klinische Studien durchführte.
- Clear quarter-on-quarter improvement in Q2 2024 with increases in revenue, gross profit, and net profit
- Maintained leading position in China's clinical service market with 12.8% market share
- Expanded global presence across 37 countries with 9,348 employees
- Rapid growth in North American clinical operations, managing over 45 ongoing clinical trials
- Strengthened capabilities in Asia-Pacific region through acquisition of Japanese CRO company Medical Edge
- Conducted over 100 Phase I-IV clinical trials in EMEA region
- Assisted in the approval of 11 new drugs in China, the U.S., and Japan
- Acquired China division of NAMSA and signed strategic cooperation agreement for global collaboration
- Expanded preclinical DMPK and bioanalytical laboratory capabilities in Europe through Frontage Holdings
- Total revenue for the first half of 2024 (3,358 million RMB) not compared to previous year, potentially indicating slower growth
- Gross profit for the first half of 2024 (1,333 million RMB) not compared to previous year, possibly suggesting margin pressure
This press release is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2024 interim results announcement and other relevant announcements published on the websites of the Shenzhen Stock Exchange (www.szse.cn) and the Stock Exchange of
All financials disclosed in this press release are presented in accordance with China Accounting Standards for Business Enterprises ("CASBE") except for those specifically noted otherwise.
Clear QoQ Improvement Seen from Q2 2024 Performance
- Total revenue achieved
1,698 million RMB , a quarter-on-quarter increase of2.3% - Gross Profit reached
705 million RMB , a quarter-on-quarter increase of12.2% - Net profit attributable to shareholders of the Company after deducting extraordinary gain or loss※ reached
337 million RMB , a quarter-on-quarter increase of11.3% .
First Half of 2024 Financial Performance
- During the reporting period, total revenue achieved
3,358 million RMB - During the reporting period, gross profit achieved
1,333 million RMB - During the reporting period, net profit attributable to shareholders of the Company after deducting extraordinary gain or loss(1) achieved
640 million RMB - Segment revenue generated from Clinical Trial Solutions reached
1,637 million RMB - Segment revenue generated from Clinical-related and Lab Services reached
RMB 1,721 million .
※Non-recurring gains and losses refer to the transactions and occasions that are not directly related to the normal operation of the Company. It is indirectly related to the normal operation of business, but due to its special and occasional nature, it affects people's ability to make normal judgments on the Company's operating performance and profitability. |
Business Highlight:
Tigermed has maintained its leading position in
On a global scale, Tigermed's clinical operations and new orders in
In the clinical trial solutions field, as of June 30, 2024, Tigermed had accumulated experience in 1,121 Regulatory Affairs projects, added 21 new
As of June 30, 2024, Tigermed assisted in the successful launch of 2 innovative medical device products. Additionally, Tigermed acquired the
In the clinical-related and lab services field, as of June 30, 2024, Tigermed Data Management & Statistical Analysis ("DMSA") had 824 ongoing DMSA projects and assisted in the approval of 11 new drugs in
As of June 30, 2024, Tigermed subsidiary --- Frontage Holdings, acquired a preclinical DMPK and bioanalytical laboratory in Nerviano (
Tigermed accelerates the expansion of the application of new technologies in clinical trials, leading the new trends in the development of clinical research. As of June 30, 2024, Tigermed assisted an American MNC pharmaceutical company in obtaining approval in
To drive sustained business growth, the company implemented a series of targeted business development strategies in the first half of 2024. Firstly, the company established special business units focused on three therapeutic areas: Cell and Gene Therapy (CGT), GLP1 Receptors, and Radiopharmaceuticals. By integrating resources and expertise, these units offer clients customized R&D strategy consulting and clinical development services. Additionally, the company formed the Clinical Operations Strategy Committee to consolidate resources and experts, enhance the depth of clinical strategies, and effectively increase the success rate of RFPs to promote order conversion.
Moreover, the company set up a Solutions Business Unit dedicated to developing long-term strategic cooperation with MNCs and providing one-stop solutions for MNCs'
Management Comments
"In the first half of 2024, despite the complexities of the international landscape and economic environment,
"Over the past two decades, our team has remained dedicated to delivering high-quality services and innovative solutions to clients worldwide, earning widespread recognition in international markets," said Ms. Xiaochun Cao, Co-Founder, Executive Director, and President of Tigermed. "We are actively expanding into key regions such as
Mr. Hao Wu, Executive Director and Co-President of Tigermed added: "As a leading provider of integrated biopharmaceutical R&D services, Tigermed will continue to enhance the quality and efficiency of our services. We will fully leverage our integrated platform's strengths, strengthen collaboration with the entire industry, accelerate the drug development process, and work together to advance the entire pharmaceutical R&D service industry, making a greater contribution to global health initiatives."
(1) Source: Frost & Sullivan |
Forward-Looking Statements
The information communicated herein may contain certain "forward-looking statements", which are not historical facts but instead include predictions about future events based on our beliefs and information currently made available to us. Although we believe that these predictions are reasonable on the date hereof, future events are inherently uncertain and these forward-looking statements may turn out to be incorrect. Forward-looking statements involve risk and uncertainty by nature because they relate to events and will depend on circumstances that will occur in the future relating to, inter alia, our ability to compete effectively, our ability to develop and market new service offerings, our ability to expand into new markets, the risks associated with listed subsidiaries of the Company, unforeseeable international tensions, regulatory or governmental scrutiny in certain countries, the impact of emergencies and other force majeure events. We undertake no obligations to update forward-looking statements or to adapt them to future events or developments except as required by applicable laws or listing rules. Any investment in any securities issued by the Company or its subsidiaries will also involve certain risks. There may be additional material risks that are currently not considered to be material or of which the Company and its advisors or representatives are unaware. Against the background of these uncertainties, you should not rely on these forward-looking statements.
About Tigermed
Tigermed (Stock code: 300347.SZ/3347.HK) is a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry. With a broad portfolio of services and a promise of quality, from preclinical development to clinical trial to commercialization, we are collaborating with over 3,000 customers and committed to moving their development journey efficiently and cost-effectively. Tigermed currently represents a worldwide network of more than 180 locations with over 10,000 employees across
View original content:https://www.prnewswire.com/news-releases/tigermed-reports-2024-interim-results-302232810.html
SOURCE Tigermed
FAQ
What was Tigermed's total revenue for Q2 2024?
How many employees does Tigermed (HNGZY) have as of June 30, 2024?
What was Tigermed's market share in China's clinical service market in 2023?
How many multi-region clinical trials (MRCTs) is Tigermed (HNGZY) currently executing?
How many new U.S. FDA IND projects did Tigermed add in the first half of 2024?
